Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -6.10% | -26.98% | -32.96% | -44.51% | -37.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.10% | -26.98% | -32.96% | -44.51% | -37.66% |
| Cost of Revenue | -2.45% | -11.63% | -17.69% | -21.39% | -16.36% |
| Gross Profit | -16.51% | -50.07% | -57.41% | -78.06% | -63.90% |
| SG&A Expenses | 8.51% | 9.34% | 8.02% | 0.82% | -2.55% |
| Depreciation & Amortization | 9.52% | 20.18% | 15.04% | 9.20% | 2.39% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.17% | -4.79% | -10.02% | -14.78% | -12.13% |
| Operating Income | -75.48% | -166.68% | -178.39% | -184.95% | -127.56% |
| Income Before Tax | -233.88% | -771.61% | -509.88% | -266.95% | -169.66% |
| Income Tax Expenses | 495.95% | -38.80% | 91.69% | -78.50% | -108.86% |
| Earnings from Continuing Operations | -259.40% | -1,840.49% | -707.16% | -348.19% | -191.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -259.40% | -1,840.49% | -707.16% | -348.19% | -191.64% |
| EBIT | -75.48% | -166.68% | -178.39% | -184.95% | -127.56% |
| EBITDA | -550.32% | -107.12% | -111.96% | -130.84% | -96.95% |
| EPS Basic | -251.72% | -2,475.26% | -771.34% | -365.43% | -198.02% |
| Normalized Basic EPS | -68.23% | -257.09% | -252.91% | -224.26% | -147.23% |
| EPS Diluted | -251.50% | -2,657.42% | -788.28% | -369.61% | -199.73% |
| Normalized Diluted EPS | -68.23% | -260.94% | -256.06% | -225.89% | -147.95% |
| Average Basic Shares Outstanding | 2.04% | -0.73% | -3.46% | -5.44% | -6.35% |
| Average Diluted Shares Outstanding | 2.04% | -1.03% | -3.74% | -5.88% | -7.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |